Stocks › RLAY
Relay Therapeutics, Inc.
RLAY·Nasdaq·
United States·USD
United States·USD$18.74
-0.65 (-3.35%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
RLAY
Relay Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RLAYS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RLAY by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Daniel S. GoldmanHouse · D · NY |
RLAYRelay Therapeutics, Inc. · Stock |
Sale $1,001 - $15,000 |
Aug 13, 2023 | Jul 12, 2023 | Filing ↗ |
Whale Activity
Position changes in RLAY reported for 2026-06-30 by 14 tracked institutional filers
- Increased5
- New0
- Held0
- Decreased2
- Closed0
- No prior filing7
| Filer | Shares | Value | Change |
|---|---|---|---|
| Casdin Capital, LLC | 16.0M | $300.0M | — |
| BlackRock, Inc. | 15.3M | $286.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.0M | $167.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.9M | $54.1M | increased |
| Alphabet Inc. | 1.4M | $26.4M | — |
| Affinity Asset Advisors, LLC | 1.1M | $19.6M | — |
| TWO SIGMA INVESTMENTS, LP | 700.9K | $13.1M | decreased |
| MILLENNIUM MANAGEMENT LLC | 591.7K | $11.1M | increased |
| Tetragon Partners GP Ltd | 570.3K | $10.7M | — |
| CITADEL ADVISORS LLC | 473.7K | $8.9M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 192.4K | $3.6M | decreased |
| Seven Fleet Capital Management LP | 178.2K | $3.3M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RLAY insiders, by quarter · Form 4
Recent Insider Transactions
384 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Bergstrom Donald APresident, R&D | Sale | −8,530 | $18.97 | $162K | Sep 8, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −17.7K | $18.94 | $336K | Sep 8, 2026 | Form 4 ↗ |
| Patel SanjivPresident and CEO · Director | Sale | −48.2K | $18.94 | $913K | Sep 8, 2026 | Form 4 ↗ |
| Rahmer PeterSee remarks | Sale | −4,508 | $20.03 | $90K | Aug 26, 2026 | Form 4 ↗ |
| SVF Pauling (Cayman) Ltd / SOFTBANK VISION FUND (AIV M2) L.P. / SB INVESTMENT ADVISERS (UK) LTD | Sale | −6.0M | n/c | — | Aug 25, 2026 | Form 4 ↗ |
| Patel SanjivPresident and CEO · Director | Sale | −48.2K | $20.33 | $980K | Aug 17, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −17.7K | $19.74 | $350K | Aug 14, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −1,459 | $18.61 | $27K | Jul 28, 2026 | Form 4 ↗ |
| Rahmer PeterSee remarks | Sale | −748 | $18.61 | $14K | Jul 28, 2026 | Form 4 ↗ |
| Bergstrom Donald APresident, R&D | Sale | −2,237 | $18.61 | $42K | Jul 28, 2026 | Form 4 ↗ |
| Patel SanjivPresident and CEO · Director | Sale | −48.2K | $19.58 | $944K | Jul 7, 2026 | Form 4 ↗ |
| Bergstrom Donald APresident, R&D | Sale | −8,660 | $18.71 | $162K | Jul 6, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −17.7K | $18.69 | $331K | Jul 6, 2026 | Form 4 ↗ |
| Rahmer PeterSee remarks | Sale | −50.0K | $19.09 | $955K | Jun 30, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −51.6K | $16.97 | $875K | Jun 22, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Option exercise | +51.6K | $4.45 | $229K | Jun 22, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −61.6K | $16.97 | $1.0M | Jun 22, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Option exercise | +61.6K | $5.22 | $321K | Jun 22, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Sale | −56.3K | $16.97 | $956K | Jun 22, 2026 | Form 4 ↗ |
| Catinazzo ThomasChief Financial Officer | Option exercise | +56.3K | $5.04 | $284K | Jun 22, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RLAY · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 6.8M | $127.2M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 6.3M | $118.0M | 1.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 4.2M | $77.9M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $36.4M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 1.9M | $36.1M | 0.41% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 1.9M | $34.8M | 1.58% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.8M | $34.4M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.8M | $33.3M | 0.10% | Jul 31, 2026 |
| Harbor Small Cap Growth Fund HARBOR FUNDS | 1.7M | $31.7M | 1.19% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund Fidelity Capital Trust | 1.7M | $31.6M | 0.43% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list RLAY's shares (CUSIP 75943R102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Michael KramarzSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
Aug 14, 2026 · ↗ - Robert Egen AtkinsonSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
Aug 14, 2026 · ↗ - Commodore Capital Master LPSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
Aug 14, 2026 · ↗ - Commodore Capital LPSCHEDULE 13G/A · passive (13G) · 12.0M shares5.5%
Aug 14, 2026 · ↗ - Perceptive Life Sciences Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 14.1M shares6.4%
Aug 10, 2026 · ↗ - Joseph EdelmanSCHEDULE 13G/A · passive (13G) · 14.1M shares6.4%
Aug 10, 2026 · ↗ - Perceptive Advisors LLCSCHEDULE 13G/A · passive (13G) · 14.1M shares6.4%
Aug 10, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 21.3M shares10.0%
Aug 7, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 21.3M shares10.0%
Aug 7, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G · passive (13G) · 20.0M shares9.4%
Aug 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Relay Therapeutics, Inc. as client
No lobbying filings found naming Relay Therapeutics, Inc. as the client.
Government Contracts
Federal awards to Relay Therapeutics, Inc. · USAspending
No federal contract awards found for Relay Therapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Relay Therapeutics, Inc.
No USPTO patent applications found for Relay Therapeutics, Inc..
Annual Financials
From RLAY's 10-K filings · XBRL
No annual XBRL figures on record for RLAY. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in RLAY's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 2.02, 9.01Material agreement · Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementMay 21, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsMay 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About Relay Therapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001812364 ↗